Hormone replacement therapy public meeting
Executive Summary
National Institutes of Health will host a public meeting to discuss results of the Women's Health Initiative trial Oct. 23-24 at 8:30 a.m. in the Natcher Conference Center. The trial was halted in July after a finding of an increased risk of breast cancer and adverse cardiovascular outcomes among subjects on Wyeth's Prempro (progestin/medroxyprogesterone) (1"The Pink Sheet" July 15, p. 11). FDA plans to host a public session in the fall to discuss whether the WHI results can be extrapolated to other combination estrogen/progestin products (2"The Pink Sheet" Aug. 19, p.11). The U.S. Preventive Services Task Force, sponsored by the Agency for Healthcare Research & Quality, plans to make public new recommendations on hormone replacement therapy use in the fall, NIH said...